Related Experiment Video
Updated: Apr 28, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation needs in asians with atrial fibrillation: a mythbuster
Zeenathnisa M Aribou1, Adrian Mondry
1Department of Medicine, National University Hospital, Singapore.
Insights
Physicians often disregard atrial fibrillation (AF) stroke risk guidelines. This review explores physician decision-making barriers to guideline adherence for Asian patients, impacting stroke prevention strategies.
Area of Science:
- Cardiology
- Public Health
- Clinical Practice Guidelines
Background:
- Atrial fibrillation (AF) significantly elevates stroke risk.
- International guidelines recommend thromboprophylaxis for AF patients based on risk scores.
- Current guideline compliance rates are suboptimal globally.
Purpose of the Study:
- To review common physician-cited reasons for disregarding AF stroke prevention guidelines.
- To investigate physician decision-making factors affecting guideline adherence in Asian populations.
Main Methods:
- Narrative review of existing literature and registry data.
- Analysis of physician decision-making processes in relation to AF management.
- Focus on evidence from the Global Anticoagulant Registry in the Field (GARFIELD).
Main Results:
- Poor compliance with AF stroke prevention guidelines is a widespread issue.
- Physician decision-making is a primary driver of guideline deviation.
- Specific barriers exist for implementing guidelines in Asian patient cohorts.
Conclusions:
- Addressing physician-centric barriers is crucial for improving AF stroke risk management.
- Understanding reasons for non-adherence can inform targeted interventions.
- Optimizing guideline implementation is essential for reducing stroke incidence in AF patients.
Abstract:
Atrial fibrillation (AF) has long been known to increase the risk of stroke. As a result, relevant international guidelines recommend that measures to reduce the risk of thrombus formation should be considered in all patients presenting with AF. Based on risk assessment scores, patients would then receive either thrombocyte aggregation inhibitors or oral anticoagulants. Despite this advice, compliance rates with the recommendations are poor across all countries surveyed. Evidence from the Global Anticoagulant Registry in the Field (GARFIELD) registry shows that major deviation from guidelines is due in large part to physicians' decision-making. In this brief narrative review, we address some of the frequent reasons cited by physicians why the guidelines are disregarded for Asian patients.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Aortic Regurgitation III: Medical Management
Venous Thrombosis IV: Nursing Management

